Insight

Emanuele Crupi: Antiangiogenic Therapy Combined with Immune Checkpoint Blockade in Urothelial Cancer

Emanuele Crupi/LinkedIn

Dec 23, 2024, 13:21

Emanuele Crupi: Antiangiogenic Therapy Combined with Immune Checkpoint Blockade in Urothelial Cancer

Emanuele Crupi, Fellow in Medical Oncology at San Raffaele University-Hospital, shared a post on LinkedIn about a recent paper by him and colleagues published in Bladder Cancer:

“Out now in Bladder Cancer.

Antiangiogenic Therapy Combined with Immune Checkpoint Blockade in Urothelial Cancer: Systematic Review and Meta-Analysis.

Spoiler candy:

Objective Response Rate

ICI-naïve (ICI-N): 34%
ICI-exposed (ICI-E): 16%

Looking forward to feedback and discussions from the community!”

“Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic review and meta-analysis”

Authors: Mohammad Moussa, Iuliia Kovalenko, Emanuele Crupi, Ekaterina Proskuriakova, Yimin Geng, Giuseppe Fallara, Raed Benkhadra, Daniele Raggi, Matthew Campbell, Pavlos Msaouel, Omar Alhalabi.

Emanuele Crupi: Antiangiogenic Therapy Combined with Immune Checkpoint Blockade in Urothelial Cancer

More posts featuring Emanuele Crupi.

antiangiogenic therapy bladder cancer cancer Daniele Raggi Ekaterina Proskuriakova Emanuele Crupi Giuseppe Fallara Iuliia Kovalenko Matthew Campbell Mohammad Moussa Omar Alhalabi OncoDaily Oncology Pavlos Msaouel Raed Benkhadra urothelial cancer Yimin Geng

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding